Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/7/2009
 
First Published:
10/25/2003
1.
Phase II Randomized Study of Tariquidar and Docetaxel in Patients With Recurrent or Metastatic Lung, Ovarian, Cervical Cancer, or Renal Cell Carcinoma (no longer accruing patients with ovarian or lung cancer as of 3/01/06)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
NCI-03-C-0284
NCT00072202
Last Modified:
9/25/2008
 
First Published:
11/20/2003
2.
Phase II Study of Combination Chemotherapy Comprising Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide and Surgery in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
NCI-04-C-0011
NCT00073996
Last Modified:
9/1/2001
 
First Published:
3/1/2000
3.
Phase I Study of XR9576 and Vinorelbine in Patients With Advanced Cancer (Summary Last Modified 09/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
NCI-00-C-0044
Last Modified:
4/5/2007
 
First Published:
4/1/2001
4.
Phase I Study of Tariquidar Combined With Docetaxel, Doxorubicin, or Vinorelbine in Children With Relapsed or Refractory Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
2 to 18
NCI
NCI-01-C-0091I
NCT00020514
Last Modified:
12/10/2007
 
First Published:
6/23/2004
5.
Diagnostic Pilot Study of Positron-Emission Tomography Imaging Using Tariquidar as a Drug Resistance Inhibitor and Technetium Tc 94m Sestamibi in Patients With Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Diagnostic
Closed
18 and over
NCI
NCI-04-C-0177
NCT00086853
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute